News

Revolutionary Needle-Free Allergy Treatment Receives U.K. Approval

Revolutionary Needle-Free Allergy Treatment Receives U.K. Approval

EURneffy®: A Breakthrough in Allergy Treatment

The recent approval of EURneffy (adrenaline nasal spray) in the United Kingdom represents a significant development in the emergency treatment of severe allergic reactions, particularly anaphylaxis. This innovative product provides a needle-free delivery method for adrenaline, offering a convenient solution for both adults and children weighing over 30 kg who suffer from severe allergies.

What Makes EURneffy Unique?

Developed by ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), EURneffy addresses a critical need for effective and user-friendly emergency allergy management. The ease of use is particularly beneficial for individuals who may be hesitant to use injectable epinephrine in emergencies due to fear of needles or complexity associated with auto-injectors.

Key Features of EURneffy

Some standout features of EURneffy include:

  • Needle-free design, which enhances patient comfort and reduces the fear associated with injections.
  • Compact size and reliable performance at higher temperatures up to 50°C.
  • Longer shelf life compared to traditional auto-injectors, encouraging consistent carry and timely use in emergencies.

Market Availability and Future Prospects

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted its approval for EURneffy, with plans for market availability expected in late Q3 2025. The U.K. stands as a significant market, being one of the largest for adrenaline auto-injectors outside of the United States.

Partnership with ALK-Abelló A/S

In a strategic move, ARS Pharma entered an exclusive licensing agreement with ALK-Abelló A/S to commercialize EURneffy across Europe, Canada, and several other international markets. This partnership will facilitate the distribution and accessibility of this life-saving treatment. Under the terms of their agreement, ARS received a substantial upfront payment alongside potential milestone payments, reinforcing their commitment to advancing allergic reaction management.

Beyond the U.K.: Global Expansion

The reach of EURneffy extends beyond the U.K., as ARS Pharma anticipates further regulatory approvals in Canada, Japan, Australia, and China, with commercial rollouts planned by early 2026. These impending market entries are set to enhance accessibility to effective allergy treatments worldwide.

Safety and Effectiveness

EURneffy is indicated for emergency treatment of Type I allergic reactions in both adult and pediatric patients over the age of four who weigh at least 33 pounds (15 kg). The product is designed for rapid administration at the first sign of allergic symptoms, with careful consideration given to ensure the safest conditions for use.

Understanding Allergic Reactions and Anaphylaxis

Anaphylaxis is a severe, life-threatening allergic reaction that can occur within minutes following exposure to allergens, which may include foods, insect stings, and certain medications. Immediate treatment with epinephrine, the active ingredient in EURneffy, is crucial in managing these critical situations. Unfortunately, many individuals diagnosed with severe allergies do not always carry their auto-injectors, highlighting the need for more user-friendly alternatives like EURneffy.

ARS Pharmaceuticals - Pioneering Allergy Management

ARS Pharmaceuticals is committed to empowering individuals at risk of severe allergic reactions. Their ongoing efforts aim to streamline emergency treatment and make life-saving medication more accessible. With the launch of EURneffy, the future of allergy management looks brighter, marking a pivotal change in how people deal with severe allergies.

Frequently Asked Questions

What is EURneffy®?

EURneffy® is an adrenaline nasal spray approved for the emergency treatment of allergic reactions, specifically anaphylaxis, in patients over 30 kg.

How does EURneffy differ from auto-injectors?

Unlike traditional auto-injectors, EURneffy is needle-free, which may encourage more individuals to carry and use it in emergencies.

When will EURneffy be available in the U.K.?

EURneffy is expected to be available in the U.K. by late Q3 2025 following regulatory approval.

Are there other markets where EURneffy will be launched?

Yes, EURneffy is also seeking regulatory approvals in Canada, Japan, Australia, and China, with expected launches by early 2026.

Who can use EURneffy?

EURneffy is suitable for adults and children aged 4 years and older who weigh at least 33 lbs (15 kg) for the treatment of severe allergic reactions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 0

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
&honey's U.S. Beauty Awards Sweep Puts Distribution in Focus

Updated Category News Views 128

Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...

Continue Reading
Jeff Stern Turns Travel Photography Into Full Attention

Updated Category News Views 57

A cancelled photography conference in March 2020 sent Jeff Stern toward the American Southwest, and that detour eventually became A Change of Scenery. Frankly, that origin has more grit than the usual polished creative-origin tale. While much of the world had stopped moving, Stern went alone, stood at White Pocket beneath a cobalt sky, and began reconsidering what he...

Continue Reading
Movement Elevates a Longtime Insider as Its New CEO

Updated Category News Views 81

Chalk dust rarely makes headlines, yet this is the sort of leadership change that can decide whether a consumer brand keeps its footing. Movement Climbing, Yoga and Fitness named Ryan Sewell chief executive officer effective November 18, 2026, with Anne-Worley Moelter moving into the chairperson role. It is a conspicuously internal handoff: Sewell started at the Boulder...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 158

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Yunnan Tin’s AI Materials Push Has Real Operating Teeth

Updated Category News Views 66

Tin rarely gets the spotlight until the machinery behind modern computing starts demanding more of it. Yunnan Tin Group is making the sensible case that this unglamorous metal can matter a great deal in semiconductors, artificial intelligence infrastructure and new-energy hardware. There is plenty of corporate ambition wrapped around that case, naturally, but a few...

Continue Reading
Baker Tilly Breach Raises Hard Questions on Vendor Risk

Updated Category News Views 30

A Quiet Vendor Failure Can Become a Loud Problem Tax files are not ordinary customer records, and that is why this reported Baker Tilly Advisory Group breach deserves more than the usual shrug people give cyber incidents. Names and addresses are bad enough; the potential exposure of Social Security numbers and other sensitive information turns a systems failure into a...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 119

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Caliway's China Clearance Speeds CBL-514's Next Test

Updated Category News Views 18

China's regulator moved faster than the calendar, and that is the one detail worth circling in red ink. Caliway Biopharmaceuticals has received authorization from the Center for Drug Evaluation under China's National Medical Products Administration to begin CBL-0102, its China study of injectable fat-reduction candidate CBL-514. For a clinical-stage company, an...

Continue Reading

Top 5 Most Recently Viewed Articles

Immuron Advances IMM-529 Development Following FDA Feedback

Updated Category News Views 289

Immuron Charts Path for Phase 2 Trial of IMM-529 Key Highlights Immuron concludes an important pre-IND meeting with the FDA regarding IMM-529, aimed at combating Clostridioides difficile infection (CDI). Previous clinical trials highlight the necessity for ongoing development of IMM-529. The company plans to submit an IND application for IMM-529 in the first half of 2025.

Continue Reading
Enefit Green to Host Webinars for Unveiling 2024 Results

Updated Category News Views 123

Join Enefit Green's Upcoming Webinars on 2024 Results Enefit Green is set to announce its Q4 and annual unaudited results for 2024. The special reveal will occur shortly after the publication of the report, allowing shareholders and investors to gain critical insights into the company's financial standing. Webinar Schedule and Details The webinars will be hosted on the...

Continue Reading
Intapp's Encouraging Earnings Fuel Stock Surge Amid Market Momentum

Updated Category News Views 197

Intapp's Strong Earnings Report Captivates Investors On a positive note for investors, U.S. stocks saw an uplifting day, with the Dow Jones index climbing approximately 250 points. The highlight of the day was the impressive performance of Intapp, Inc. Shares of Intapp, Inc. (NASDAQ: INTA) experienced a sharp increase following the company's announcement of...

Continue Reading
NewAmsterdam Pharma's Upcoming Conference Participation for 2024

Updated Category News Views 229

NewAmsterdam Pharma Announces Conference Participation NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) is gearing up for an exciting lineup of presentations at key medical and investor conferences. As a leader in developing innovative oral therapies for cardiovascular disease, NewAmsterdam is set to share groundbreaking research findings and engage with stakeholders in...

Continue Reading
John Hancock Funds Announce Monthly Distribution Updates

Updated Category News Views 366

Monthly Distribution Announcements from John Hancock Funds John Hancock has announced important updates regarding the distributions for its closed-end funds. These monthly distributions aim to provide returns to investors, ensuring they receive value from their investments in a timely manner. Details of the Monthly Distribution Declaration Key Dates Recently, the board of...

Continue Reading